Pharmaceutical - Markets & Marketing, Rare diseases


Popular Filters

1 to 25 of 30 results

Ipsen takes step forward in the resupply of Increlex for the USA

Ipsen takes step forward in the resupply of Increlex for the USA


Following previous availability problems, French drugmaker Ipsen said today that a supply of Increlex…

IncrelexIpsenMarkets & MarketingPharmaceuticalProductionRare diseasesUSA

Marken ready for orphan drug distribution


USA-based Marken, a global clinical supply chain solutions provider, has released a new white paper which…

Markets & MarketingPharmaceuticalProductionRare diseases

Jazz Pharma and Gentium debut Defitelio in Europe


Ireland-headquartered Jazz Pharmaceuticals and its Italian subsidiary Gentium have initiated the European…

AustriaDefitelioEuropeGentiumGermanyJazz PharmaceuticalsMarkets & MarketingPharmaceuticalRare diseases

Which place for orphan drugs in the strategy of pharma companies and payers?


As the 7th Rare Disease Day will be held on February 28, ALCIMED, an innovation and new business consulting…

Markets & MarketingNovartisPharmaceuticalPricingRare diseasesResearchRocheSanofi

US orphan drug market outlook 2018: Report


In the largest market for orphan drugs, the USA, there was a shortage of adequate therapies for treating…

Markets & MarketingNorth AmericaPharmaceuticalRare diseasesRegulationUSA

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler


French drugmaker Ipsen says that Lonza has successfully re-manufactured the active ingredient of Increlex…

Anti-Arthritics/RheumaticsEuropeGastro-intestinalsIncrelexIpsenLonzaMarkets & MarketingMayoly SpindlerPharmaceuticalProductionRare diseases

Daiichi Sankyo launches Biopten Granules 10% in Japan

Daiichi Sankyo launches Biopten Granules 10% in Japan


Japanese drug major Daiichi Sankyo has launched natural tetrahydrobiopterin agent Biopten Granules 10%…

Asia-PacificBioptenDaiichi SankyoMarkets & MarketingPharmaceuticalRare diseases

Eisai's new Belgium operation to help firm's globalization aims


Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania), a division of Japanese drug major Eisai…

EisaiEuropeHalavenInovelonMarkets & MarketingOncologyPharmaceuticalRare diseases

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData


Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Protalix BioTherapeutics enters Gaucher drug Uplyso deal with Brazil's Ministry of Health


Israel-based Protalix BioTherapeutics (TASE:PLX) has entered into a supply and technology transfer agreement…

FiocruzMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesSouth AmericaUplyso

Orphan diseases' appeal lies in return on investment, says Evaluate


For many years, Big Pharma's model of success has been the blockbuster: drugs that sell more than $1…

BiotechnologyFinancialMarkets & MarketingPharmaceuticalRare diseasesResearch

Roche and Isis Pharma in up to $392 million deal on Huntington's research


Swiss drug major Roche (ROG: SIX) and USA-based Isis Pharmaceuticals (Nasdaq: ISIS) have formed an alliance…

Isis PharmaceuticalsLicensingMarkets & MarketingPharmaceuticalRare diseasesResearchRoche

Global orphan drugs market led by Roche's rituximab


The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

Stagnant treatment future seen for inherited orphan blood diseases


Generally unimpressive treatment line-ups combined with weak product pipelines will lead to modest growth…

CinryzeMarkets & MarketingPharmaceuticalRare diseasesViroPharma

Teijin debuts Ipsen's Somatuline in Japan; Galenica deal for Maltofer and Uro-Vaxom in China


Teijin Pharma, the core company of the Japanese Teijin Group (TYO: 3401) health care business, and French…

Asia-PacificChina Medical SystemGalenicaIpsenLicensingMaltoferMarkets & MarketingPharmaceuticalRare diseasesSomatulineTeijinUro-VaxomVifor Pharma

Benlysta will be lupus market leader in 2021 with sales of more than $1.7 billion, says DR


In the systemic lupus erythematosus (SLE) drug market, Human Genome Sciences/GlaxoSmithKline's (LSE:…

BenlystaBiotechnologyGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRare diseases

Denmark sees first launches of Almirall's Eklira Genuair and ViroPharma's Plenadren


Spain's largest drugmaker, Almirall (ALM: MC), says that the Danish Health and Medicines Authority has…

AlmirallEklira GenuairEuropeMarkets & MarketingPharmaceuticalPlenadrenRare diseasesRespiratory and PulmonaryViroPharma

GlaxoSmithKline expands Fabry disease deal with Amicus, upping stake in the firm


Moving forward with its foray into the rare disease sector, UK pharma giant GlaxoSmithKline (LSE: GSK)…

Amicus TherapeuticsAmigalBiotechnologyGlaxoSmithKlineMarkets & MarketingPharmaceuticalRare diseasesResearch

Elelyso: a new therapeutic option for patients with Gaucher disease


The US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso…

CerezymeElelysoGenzymeMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesShireVpriv

Benlysta continues to penetrate lupus market one year post-launch; report


More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceuticalRare diseases

Unmet needs in orphan diseases therapy offer opportunity for Big Pharma; report


Patients suffering from orphan diseases can look forward to a wider range of drug options in the future,…

BiotechnologyMarkets & MarketingPharmaceuticalRare diseasesResearch

Drug shortages spur developments in neurometabolic treatments


A prolonged gap in the neurology market following the shutdown of a Genzyme production facility is tempting…

BiotechnologyMarkets & MarketingNeurologicalPharmaceuticalRare diseasesResearch

1 to 25 of 30 results

Back to top